Results 91 to 100 of about 1,619,987 (346)

Non-clinical studies in the process of new drug development - Part II: Good laboratory practice, metabolism, pharmacokinetics, safety and dose translation to clinical studies

Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas, 2016
The process of drug development involves non-clinical and clinical studies. Non-clinical studies are conducted using different protocols including animal studies, which mostly follow the Good Laboratory Practice (GLP) regulations.
E. L. Andrade, A. Bento, J. Cavalli, S. K. Oliveira, R. C. Schwanke, J. M. Siqueira, C. S. Freitas, R. Marcon, João B. Calixto   +8 more
semanticscholar   +1 more source

Bridging the gap: Multi‐stakeholder perspectives of molecular diagnostics in oncology

Molecular Oncology, EarlyView.
Although molecular diagnostics is transforming cancer care, implementing novel technologies remains challenging. This study identifies unmet needs and technology requirements through a two‐step stakeholder involvement. Liquid biopsies for monitoring applications and predictive biomarker testing emerge as key unmet needs. Technology requirements vary by
Jorine Arnouts, Senada Koljenović, Elise Daems, Karolien De Wael, Marc Peeters, Léon C. van Kempen, Greetje Vanhoutte, Karen Zwaenepoel, Timon Vandamme   +8 more
wiley   +1 more source

Information system of the national network of public health laboratories in Peru (NETLAB)

Revista Peruana de Medicina Experimental y Salud Pública, 2015
Clinical laboratory information systems produce improvements in the quality of information, reduce service costs, and diminish wait times for results, among other things.
Javier Vargas-Herrera, José Segovia-Juarez, Gladys María Garro Nuñez   +2 more
doaj   +1 more source

Loss of correlation between HIV viral load and CD4+ T-cell counts in HIV/HTLV-1 co-infection in treatment naive Mozambican patients [PDF]

, 2009
Seven hundred and four HIV-1/2-positive, antiretroviral therapy (ART) naïve patients were screened for HTLV-1 infection. Antibodies to HTLV-1 were found in 32/704 (4.5%) of the patients.
Augusto, O, Bhatt, N B, Bila, D, Di Mattei, P, Garsia, R, Gudo, E S, Jani, I V, Semá, C   +7 more
core   +2 more sources

Investigating the cell of origin and novel molecular targets in Merkel cell carcinoma: a historic misnomer

Molecular Oncology, EarlyView.
This study indicates that Merkel cell carcinoma (MCC) does not originate from Merkel cells, and identifies gene, protein & cellular expression of immune‐linked and neuroendocrine markers in primary and metastatic Merkel cell carcinoma (MCC) tumor samples, linked to Merkel cell polyomavirus (MCPyV) status, with enrichment of B‐cell and other immune cell
Richie Jeremian, Sriraam Sivachandran, Melissa Galati, Brandon Ramchatesingh, Hibo Rijal, Johnny Hanna, Elena Netchiporouk, May Chergui, Margaret Redpath, Samy Abou Setah, Ivan V. Litvinov   +10 more
wiley   +1 more source

Integration technologies in laboratory information systems: A systematic review

Informatics in Medicine Unlocked
Clinical laboratories have evolved with technological advancements through integrating various subsystems into Health Information Systems (HIS), particularly the Laboratory Information System (LIS).
Jay Mark Edayan, Arthon Jon Gallemit, Niña Eunice Sacala, Xavier-Lewis Palmer, Lucas Potter, Junil Rarugal, Lemuel Clark Velasco   +6 more
doaj   +1 more source

Performance Measures Using Electronic Health Records: Five Case Studies [PDF]

, 2008
Presents the experiences of five provider organizations in developing, testing, and implementing four types of electronic quality-of-care indicators based on EHR data.
Brian L. Hazlehurst, Dean F. Sittig, Elizabeth A. Kind, James T. Krizak, Jinnet Briggs Fowles, Jonathan P. Weiner, Kitty S. Chan, Lynne Dancha, Mark J. Selna, Nancy Jarvis, Patricia J. Coon, Shadi Awwad   +11 more
core  

The continued value of disk diffusion for assessing antimicrobial susceptibility in clinical laboratories: Report from the Clinical and Laboratory Standards Institute Methods Development and Standardization Working Group [PDF]

, 2018
Expedited pathways to antimicrobial agent approval by the U.S. Food and Drug Administration (FDA) have led to increased delays between drug approval and the availability of FDA-cleared antimicrobial susceptibility testing (AST) devices.
Burnham, Carey-Ann D, Ferrell, Andrea, Hsiung, Andre, Humphries, Romney M, Kircher, Susan, Krause, Kevin M, Malherbe, Rianna   +6 more
core   +2 more sources

PYCR1 inhibition in bone marrow stromal cells enhances bortezomib sensitivity in multiple myeloma cells by altering their metabolism

Molecular Oncology, EarlyView.
This study investigated how PYCR1 inhibition in bone marrow stromal cells (BMSCs) indirectly affects multiple myeloma (MM) cell metabolism and viability. Culturing MM cells in conditioned medium from PYCR1‐silenced BMSCs impaired oxidative phosphorylation and increased sensitivity to bortezomib.
Inge Oudaert, Lauren van den Broecke, Osman Aksoy, Judith Lind, Sonia Vallet, Arne Van der Vreken, Gamze Ates, Ann Massie, Ken Maes, Kim De Veirman, Elke De Bruyne, Karin Vanderkerken, Klaus Podar, Eline Menu   +13 more
wiley   +1 more source

Inhibition of CDK9 enhances AML cell death induced by combined venetoclax and azacitidine

Molecular Oncology, EarlyView.
The CDK9 inhibitor AZD4573 downregulates c‐MYC and MCL‐1 to induce death of cytarabine (AraC)‐resistant AML cells. This enhances VEN + AZA‐induced cell death significantly more than any combination of two of the three drugs in AraC‐resistant AML cells.
Shuangshuang Wu, Jianlei Zhao, Aaban Asfar Azmi, Avanti Gupte, Jenna Thibodeau, Shuang Liu, Jinli Yang, Guan Wang, Holly Edwards, Lisa A. Polin, Juiwanna Kushner, Sijana H. Dzinic, Kathryn White, Julie Boerner, Maik Hüttemann, Jay Yang, Yue Wang, Jeffrey W. Taub, Yubin Ge   +18 more
wiley   +1 more source